Reports Q1 revenue $20.27M vs. $2.21M last year. The company said, “Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S. commercial rights for Mytesi and Canalevia.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Animal Health Issues Series Q Preferred Stock
- Jaguar says first patient from pediatric MVID entered active treatment
- Jaguar Health Delays Quarterly Filing Briefly
- Jaguar Health granted extension to comply with Nasdaq bid price rule
- Jaguar Animal Health Granted Short Nasdaq Compliance Extension